Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph not_applicable
1
50%
Ph phase_3
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(1)
Other(1)

Detailed Status

unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (50.0%)
N/A1 (50.0%)

Trials by Status

unknown150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
terminatednot_applicable

Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C

NCT01639547
unknownphase_3

Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C

NCT00154869

Clinical Trials (2)

Showing 2 of 2 trials
NCT01639547Not Applicable

Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C

Terminated
NCT00154869Phase 3

Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2